Miochol-E: Uses, Dosage & Side Effects

What Is Miochol-E and What Is It Used For?

Miochol-E contains the active substance acetylcholine chloride, the endogenous neurotransmitter responsible for transmitting nerve impulses at cholinergic synapses throughout the body. In physiological terms, acetylcholine is the principal neurotransmitter of the parasympathetic nervous system and plays a critical role in many bodily functions, including muscle contraction, glandular secretion, heart rate regulation, and — most relevant to ophthalmology — control of pupil size and accommodation of the lens.

When acetylcholine is released from parasympathetic nerve endings that innervate the iris sphincter muscle (the musculus sphincter pupillae), it binds to muscarinic receptors (predominantly the M3 subtype) on the smooth muscle fibers, causing them to contract. This contraction pulls the pupillary margin toward the center, resulting in miosis (constriction of the pupil). Under normal physiological conditions, this process occurs as part of the pupillary light reflex and the accommodation reflex. Miochol-E harnesses this same mechanism by delivering exogenous acetylcholine directly into the anterior chamber of the eye during surgery, bypassing the normal nerve-mediated pathway to produce immediate, reliable pupil constriction.

The formulation of Miochol-E has been specifically designed for intraocular use. The powder component contains acetylcholine chloride 20 mg (which, upon reconstitution with 2 mL of the accompanying solvent, yields a 10 mg/mL solution). The solvent contains mannitol as an osmotic agent to ensure that the reconstituted solution has an osmolarity compatible with the delicate intraocular environment, preventing damage to the corneal endothelium and other sensitive ocular structures. Electrolytes such as potassium chloride, calcium chloride, and magnesium chloride are also included to approximate the ionic composition of aqueous humor.

Miochol-E is indicated for use in the following ophthalmic surgical procedures where intraoperative miosis is required:

• Cataract extraction with intraocular lens (IOL) implantation: This is by far the most common indication. During phacoemulsification or extracapsular cataract extraction, the surgeon may need to constrict the pupil at various stages — for example, after lens implantation to check IOL centration, to reduce the risk of vitreous prolapse, or to restore the pupil to its physiological state before wound closure. Miochol-E provides rapid, predictable miosis that allows the surgeon to verify proper IOL positioning and to complete the procedure safely.
• Penetrating keratoplasty (corneal transplant): During full-thickness corneal transplantation, the anterior chamber is fully opened, creating a risk of iris prolapse and lens damage. A constricted pupil helps protect the crystalline lens and maintains the structural integrity of the anterior segment during the delicate graft suturing process.
• Iridectomy: Surgical procedures that involve excision of a portion of the iris (peripheral iridectomy for angle-closure glaucoma, or sector iridectomy for diagnostic or therapeutic purposes) may require controlled miosis to manage iris tissue and reduce bleeding.
• Other anterior segment surgeries: Miochol-E may also be used during trabeculectomy (glaucoma filtration surgery), anterior vitrectomy, and other procedures where a constricted pupil provides a safer surgical field or reduces the risk of complications such as vitreous loss.

From a pharmacokinetic standpoint, the effect of Miochol-E is characteristically rapid in onset and short in duration. Upon instillation into the anterior chamber, miosis begins within seconds and typically reaches its maximum within 20–60 seconds. The effect is transient, lasting approximately 10–20 minutes under normal circumstances. This brevity is due to the rapid enzymatic hydrolysis of acetylcholine by two classes of cholinesterase enzymes present in ocular tissues: acetylcholinesterase (AChE), which is found in the iris and ciliary body, and pseudocholinesterase (butyrylcholinesterase, BuChE), which is present in plasma and various tissues. The hydrolysis products — choline and acetic acid — are pharmacologically inactive and are safely metabolized or excreted.

Miochol-E was first developed and introduced by Iolab Corporation (subsequently acquired by Johnson & Johnson Vision, and later by Bausch + Lomb). It has been available for clinical use since the late 1970s and remains a standard miotic agent in ophthalmic operating rooms worldwide. The product is approved by regulatory authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and it is included in national formularies across Europe, North America, Asia-Pacific, and other regions. Despite the availability of alternative intraoperative miotic strategies (such as intracameral phenylephrine-ketorolac combinations or pupil expansion devices), Miochol-E remains the most widely used direct-acting intraocular miotic because of its rapid onset, predictable efficacy, and established safety record spanning more than four decades.

What Should You Know Before Taking Miochol-E?

Contraindications

The primary absolute contraindication to Miochol-E is known hypersensitivity to acetylcholine chloride or to any of the excipients in the formulation (mannitol, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, sodium acetate trihydrate, and water for injections). Allergic reactions to acetylcholine itself are exceedingly rare, as it is an endogenous neurotransmitter, but sensitivity to excipients is possible and should be ascertained before use.

There are no other absolute contraindications to the intraocular use of Miochol-E in the context of ophthalmic surgery. However, the decision to use any intraocular agent must be made by the operating surgeon based on a comprehensive assessment of the individual patient’s medical history, the specific surgical procedure, and the anticipated benefits and risks. In general, if miosis is not required or is contraindicated for the specific surgical procedure (for example, during certain posterior segment surgeries where a dilated pupil is needed), Miochol-E should not be administered.

Warnings and Precautions

Although systemic absorption from intraocular administration is generally minimal, the surgeon should be aware of the following precautions:

• Bronchial asthma: Acetylcholine is a cholinergic agonist that can theoretically induce bronchoconstriction via stimulation of muscarinic receptors on bronchial smooth muscle. While clinically significant systemic absorption from a single intraocular dose is uncommon, patients with active or severe asthma should be monitored for signs of respiratory distress during and after the procedure.
• Heart failure and bradycardia: Cholinergic stimulation can decrease heart rate and cardiac output. Patients with pre-existing heart failure, symptomatic bradycardia, or second/third-degree atrioventricular block should be monitored with appropriate cardiac monitoring during surgery when Miochol-E is used.
• Peptic ulcer disease: Acetylcholine stimulates gastric acid secretion via vagal muscarinic pathways. Although systemic effects from intraocular use are rare, patients with active peptic ulcer disease should be treated with caution.
• Hyperthyroidism: Patients with hyperthyroidism may have an altered cardiovascular response to cholinergic agents. Appropriate monitoring is recommended.
• Urinary tract obstruction: Cholinergic agents can increase detrusor muscle tone and urinary frequency. Patients with obstructive uropathy or bladder outlet obstruction should be used with caution, although clinically significant effects from intraocular use are extremely unlikely.
• Parkinson’s disease: Cholinergic agents may theoretically exacerbate parkinsonian symptoms by increasing cholinergic tone in the basal ganglia. The clinical significance in the context of a single intraocular dose is negligible, but the surgeon should be aware of the patient’s neurological status.

Preparation and Handling

Miochol-E is supplied as a two-component system: a vial of sterile lyophilized acetylcholine chloride powder and a separate container of diluent. The two components must be mixed together immediately before use according to the manufacturer’s instructions. The reconstituted solution should be clear and colorless. Do not use if the solution is discolored, turbid, or contains visible particulate matter. Once reconstituted, the solution is chemically unstable and must be used promptly. Any unused portion must be discarded at the end of the surgical procedure. Do not store or re-sterilize reconstituted solution.

It is critically important that the reconstituted solution is prepared using aseptic technique in a sterile field to prevent intraocular contamination and the risk of endophthalmitis, a devastating intraocular infection that can result in permanent vision loss. Only qualified ophthalmic nursing or surgical staff should prepare the solution under the direction of the operating surgeon.

Pregnancy and Breastfeeding

There are no adequate and well-controlled studies of Miochol-E in pregnant women. Acetylcholine is an endogenous neurotransmitter present in all humans, and the intraocular dose used in surgery is very small with minimal systemic absorption. Animal reproductive toxicity studies have not been conducted specifically with Miochol-E. In general, the risk to the fetus from a single intraocular dose of acetylcholine during a necessary surgical procedure is considered negligible. However, as with all medications during pregnancy, Miochol-E should only be used if the expected benefit to the mother justifies the potential risk. The decision should be made by the surgeon in consultation with the patient and, if relevant, the patient’s obstetrician.

It is not known whether acetylcholine chloride administered intraocularly is excreted in human breast milk. Given the rapid enzymatic hydrolysis of acetylcholine (half-life of seconds) and the minimal systemic absorption from intraocular use, any amount reaching breast milk would be clinically insignificant. Breastfeeding is generally considered compatible with the intraocular use of Miochol-E during surgery. However, patients should discuss any concerns with their healthcare provider.

Children and Adolescents

Miochol-E may be used in pediatric patients when intraocular miosis is required during ophthalmic surgery. Congenital cataract surgery, for example, is performed in infants and children and may require intraoperative miotic agents. The dosage and administration are at the discretion of the operating surgeon, based on the specific surgical requirements and the child’s individual clinical circumstances. Pediatric patients may be more susceptible to systemic cholinergic effects due to lower body weight and higher surface area-to-volume ratio, and appropriate monitoring should be in place.

How Does Miochol-E Interact with Other Drugs?

Because Miochol-E is administered as a single intraocular dose during surgery, the scope of drug interactions is more limited than with systemically administered medications. However, several clinically important interactions can affect the efficacy and safety of intraoperative miosis:

Major Interactions

The following drug interactions are considered clinically significant and may require modification of the surgical approach:

Minor Interactions

The following interactions are of lower clinical significance but should be documented in the surgical record:

In clinical practice, the interaction with preoperative topical NSAIDs is the most commonly encountered and clinically relevant. Many cataract surgeons routinely prescribe topical NSAIDs (such as ketorolac 0.5% or nepafenac 0.1%) before surgery to help maintain mydriasis and reduce postoperative inflammation. However, prostaglandins are also involved in the miotic response to surgical trauma, and their inhibition can impair the ability of Miochol-E to produce complete miosis. Surgeons must balance the anti-inflammatory benefits of preoperative NSAIDs against the potential need for effective intraoperative miosis, and should have contingency plans (such as pupil expansion rings or iris hooks) available if pharmacological miosis proves inadequate.

Similarly, the residual effects of preoperative mydriatic agents (tropicamide, phenylephrine, cyclopentolate) used to dilate the pupil for cataract surgery can partially antagonize the miotic effect of Miochol-E when it is administered later in the procedure. This is expected and managed by timing — by the time Miochol-E is typically used (toward the end of the procedure), the mydriatic agents have begun to wear off, allowing acetylcholine to overcome the residual dilation. In cases of floppy iris syndrome (often associated with alpha-blocker use such as tamsulosin), the pupillary response may be less predictable, and the surgeon should be prepared for suboptimal miosis.

What Is the Correct Dosage of Miochol-E?

Adults

In adult patients, Miochol-E is administered as an intracameral instillation (directly into the anterior chamber of the eye) during surgery. The reconstituted solution contains acetylcholine chloride 10 mg/mL. The surgeon gently instills the solution into the anterior chamber using a blunt cannula or irrigating handpiece, typically after aspiration of the viscoelastic material and before or after intraocular lens implantation, depending on the surgical technique.

The exact volume used depends on the size of the anterior chamber, the stage of surgery, and the degree of residual mydriasis that needs to be overcome. In most routine cataract procedures, approximately 0.5–1 mL is sufficient to produce complete miosis. In more complex situations (e.g., residual effects of strong mydriatics, floppy iris syndrome, or large anterior chamber volumes in highly myopic eyes), the surgeon may use up to 2 mL or may repeat the instillation if the initial application produces an incomplete response.

Children

The dosage of Miochol-E in pediatric patients is determined by the operating surgeon on a case-by-case basis. Children undergoing congenital cataract surgery or other anterior segment procedures may require proportionally smaller volumes due to the smaller anterior chamber volume of pediatric eyes. However, the concentration of the reconstituted solution (10 mg/mL) remains the same. The surgeon adjusts the volume instilled according to the observed pupillary response and the specific surgical requirements. Pediatric patients should have appropriate vital sign monitoring throughout the procedure.

Elderly

No specific dosage adjustment is required for elderly patients. Cataract surgery is most commonly performed in elderly adults, and Miochol-E has been used safely in this population for decades. However, elderly patients are more likely to have coexisting conditions (such as cardiovascular disease or chronic obstructive pulmonary disease) that may warrant additional monitoring for potential systemic cholinergic effects, even though these are rare with intraocular use. The surgeon should review the patient’s medical history and ensure that the anesthesia team is aware of the use of cholinergic agents.

Reconstitution Instructions

Miochol-E must be reconstituted immediately before use. The preparation steps are as follows:

1. Open the outer packaging under aseptic conditions and remove the vial of lyophilized acetylcholine chloride powder and the container of diluent.
2. Using the integrated transfer system or a sterile syringe, transfer the entire contents of the diluent container into the vial containing the powder.
3. Gently swirl or rotate the vial to dissolve the powder completely. Do not shake vigorously, as this may cause foaming.
4. Inspect the reconstituted solution visually. It should be clear and colorless. Do not use if the solution is turbid, discolored, or contains particulate matter.
5. Using a sterile blunt-tipped cannula or irrigation system, draw up the required volume for intraocular instillation.
6. Discard any unused portion of the reconstituted solution. Do not store or resterilize.

Missed Dose

The concept of a missed dose does not apply to Miochol-E, as it is a single-use surgical agent administered once (or occasionally repeated) during an ophthalmic procedure. It is not a medication taken on a scheduled basis.

Overdose

Overdose with Miochol-E in the intraocular setting is unlikely, as the surgeon directly visualizes the anterior chamber and controls the volume instilled. If an excessively large volume were inadvertently administered, the primary local effect would be prolonged or exaggerated miosis and possible transient hypotony (low intraocular pressure) due to increased aqueous outflow. Systemic effects from intraocular overdose are theoretically possible but exceedingly rare; they could include bradycardia, hypotension, bronchospasm, increased salivation, and diaphoresis (sweating). Treatment would be supportive, and atropine sulfate (0.5–1 mg intravenously) could be administered to reverse systemic muscarinic effects if clinically indicated.

What Are the Side Effects of Miochol-E?

As a direct-acting cholinergic agent with a very short duration of action, Miochol-E has a relatively favorable safety profile when used as intended (single intraocular dose during surgery). However, both local (ocular) and systemic side effects have been reported. The frequency classifications below are based on post-marketing surveillance data, published literature, and regulatory agency safety reports.

Ocular Side Effects in Detail

Corneal edema is the most frequently observed ocular side effect and is usually transient, resolving within hours to days after surgery. It is partly related to the surgical procedure itself (mechanical and ultrasonic trauma to the corneal endothelium during phacoemulsification) rather than exclusively to Miochol-E. However, the introduction of any additional fluid into the anterior chamber, including acetylcholine solution, contributes to endothelial cell exposure and may transiently increase corneal thickness. The mannitol in the Miochol-E formulation helps minimize osmotic damage to the endothelium, but some degree of transient edema is expected in many cases.

Corneal decompensation (persistent corneal edema that does not resolve) is uncommon and is typically multifactorial, resulting from a combination of pre-existing endothelial dysfunction (e.g., Fuchs’ endothelial dystrophy), surgical trauma, and the intraocular agents used during the procedure. It is rarely attributable to Miochol-E alone.

Transient hypotony (temporary reduction in intraocular pressure) occurs because acetylcholine stimulates contraction of the ciliary muscle, which opens the trabecular meshwork and increases aqueous humor outflow through the conventional pathway. This is generally self-limiting and resolves as the acetylcholine is hydrolyzed. In most cases, the mild reduction in intraocular pressure is not clinically significant and may even be advantageous in the immediate postoperative period.

Systemic Side Effects in Detail

Systemic cholinergic effects are rare following intraocular administration of Miochol-E because the dose is small and acetylcholine is rapidly hydrolyzed by cholinesterase enzymes before it can reach the systemic circulation in pharmacologically significant amounts. When systemic effects do occur, they are most commonly cardiovascular (bradycardia, hypotension) and are usually mild and self-limiting. The risk is slightly higher in patients taking systemic cholinesterase inhibitors (e.g., donepezil for Alzheimer’s disease or pyridostigmine for myasthenia gravis), as these drugs slow the breakdown of acetylcholine and may allow higher circulating levels.

Respiratory effects (bronchospasm) are primarily a concern in patients with pre-existing asthma or chronic obstructive pulmonary disease (COPD). The anesthesia team should be informed when Miochol-E is to be used in such patients, and bronchodilators should be readily available.

How Should You Store Miochol-E?

Proper storage of Miochol-E is essential to maintain the stability and sterility of the product. Acetylcholine chloride in its lyophilized (freeze-dried) form is relatively stable when stored under the correct conditions, but it is highly susceptible to degradation once reconstituted due to the rapid hydrolysis by even trace amounts of cholinesterase enzymes and spontaneous chemical decomposition in aqueous solution.

The following storage requirements apply to the unopened product:

• Temperature: Store at 2–8 °C (36–46 °F) in a refrigerator. Do not freeze. Freezing may damage the vial, compromise the sterile seal, or alter the reconstitution properties of the lyophilized powder.
• Light protection: Keep the product in its original outer packaging to protect from light. Acetylcholine chloride can undergo photodegradation when exposed to strong light sources.
• Shelf life: The shelf life of the unopened product is typically 18–24 months from the date of manufacture when stored as directed. Always check the expiry date printed on the packaging before use. Do not use expired product.
• Integrity: Before use, inspect the packaging for any signs of damage, such as cracks in the vial, discoloration of the powder, or breaches in the sterile seal. Do not use if any damage is observed.

After reconstitution, the solution must be used immediately. The reconstituted acetylcholine chloride solution is chemically unstable and begins to lose potency within minutes as the acetylcholine undergoes hydrolysis. Additionally, once the sterile vial has been opened and the solution prepared, it is no longer considered sterile for prolonged periods and must not be stored for later use. Any unused reconstituted solution, along with the vial and all associated preparation materials, should be disposed of in accordance with local hospital waste management guidelines for pharmaceutical products.

For operating room logistics, it is recommended that the hospital pharmacy or surgical department maintain a dedicated refrigerated storage area for ophthalmic surgical agents, with regular inventory checks and expiry date monitoring. Miochol-E should be transported to the operating room in a cool container if the journey from the pharmacy exceeds the recommended temperature excursion parameters. The product should not be removed from the refrigerator and stored at room temperature for extended periods before use.

What Does Miochol-E Contain?

Active Ingredient

The active substance is acetylcholine chloride. Each vial contains 20 mg of acetylcholine chloride as a sterile, white to off-white lyophilized powder. Upon reconstitution with the accompanying 2 mL of diluent, the resulting solution has a concentration of 10 mg/mL of acetylcholine chloride, equivalent to approximately 7 mg/mL of acetylcholine base.

Acetylcholine (chemical formula: C₇H₁₆NO₂⁺) is the ester of acetic acid and choline. It is the principal neurotransmitter at all cholinergic synapses in the body, including the neuromuscular junction, autonomic ganglia, and postganglionic parasympathetic nerve endings. In its chloride salt form, it is water-soluble and suitable for pharmaceutical formulation. The molecular weight of acetylcholine chloride is 181.66 g/mol.

Excipients

The complete list of excipients in Miochol-E is as follows:

The formulation does not contain preservatives such as benzalkonium chloride, which are commonly found in topical ophthalmic preparations but are inappropriate for intraocular use due to their toxicity to the corneal endothelium and other intraocular structures. The preservative-free nature of Miochol-E is essential for its safety in the intraocular environment, but it also means that the reconstituted solution has no antimicrobial protection and must be used immediately and then discarded.

The careful selection and balance of electrolytes in the diluent is a key feature of the Miochol-E formulation. The anterior chamber of the eye is a delicate environment, and the introduction of solutions with inappropriate osmolarity or ionic composition can cause immediate and potentially irreversible damage to the corneal endothelium, a monolayer of cells that is essential for maintaining corneal clarity. The mannitol-based, electrolyte-balanced diluent in Miochol-E has been specifically formulated to minimize endothelial toxicity, as demonstrated in both in vitro endothelial cell studies and extensive clinical use.